Breaking news: CDC announces shortage of antimalarial drug primaquine
The Centers for Disease Control and Prevention warned this week that the antimalarial drug primaquine is not available until September, 2011.
The Centers for Disease Control and Prevention (CDC) warned this week that the antimalarial drug primaquine is not available until September, 2011.
Primaquine’s manufacturer, Sanofi-Aventis, reported the drug shortage to the CDC. Sanofi-Aventis representatives did not respond to Formulary’s request for comment.
“Primaquine is the only drug that can be used to eliminate hypnozoites, the dormant forms of malaria parasites,” the CDC said in a statement. Still, healthcare providers may choose to maintain persons at risk of relapse on weekly chloroquine prophylaxis until primaquine is available again.
“Additionally, during the shortage, primaquine should not be prescribed for primary chemoprophylaxis,” the CDC stated.
Besides primaquine and chloroquine, medications recommended to treat malaria include atovaquone/proguanil, doxyclycline, and mefloquine.
Nearly 82 million malaria cases were reported worldwide in 2009, with the highest prevalence in Uganda, Kenya, and the Democratic Republic of Congo.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
